Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease [Yahoo! Finance Canada]
MeiraGTx Holdings plc - Ordinary Shares (MGTX)
Company Research
Source: Yahoo! Finance Canada
Shares ?of the gene therapy developer rose 12.5% to $9.55 in premarket trading on Monday after the news. Under the deal, MeiraGTx will get an upfront payment of $75 million and potentially over $400 ?million more in milestone payments.? MeiraGTx is also eligible to receive tiered royalties on licensed products. This marks Lilly's latest effort to ?tap the market for eye treatments and bolster its focus on gene therapies, after signing a deal valued at up to $261.7 million to ?buy gene therapy developer Adverum Biotechnologies in October. Adverum is ?developing an eye injection for wet age-related macular degeneration, or wAMD, a leading cause of blindness among the elderly. MeiraGTx's experimental therapy, AAV-AIPL1, is being studied to treat one of the most severe forms of Leber congenital amaurosis 4, ?caused by mutations in the AIPL1 gene,? and is delivered via subretinal injection ?to children. Through a one-time administration, AAV-AIPL1 is designed to deliver functional
Show less
Read more
Impact Snapshot
Event Time:
MGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTX alerts
High impacting MeiraGTx Holdings plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MGTX
News
- MeiraGTx (NASDAQ:MGTX) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
- MeiraGTx (NASDAQ:MGTX) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.MarketBeat
- Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx ConferencePR Newswire
- MeiraGTx (NASDAQ:MGTX) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- MeiraGTx Reports Third Quarter 2025 Financial and Operational ResultsGlobeNewswire
MGTX
Earnings
- 11/13/25 - Miss
MGTX
Sec Filings
- 11/24/25 - Form 4
- 11/13/25 - Form SCHEDULE
- 11/13/25 - Form 10-Q
- MGTX's page on the SEC website